Search results for: psoriatic arthritis

Health Canada Approves Upadacitinib to Treat Adults with PsA

Michele B. Kaufman, PharmD, BCGP | July 6, 2021

Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.

Risankizumab May Improve Symptoms of PsA

Michele B. Kaufman, PharmD, BCGP | January 21, 2021

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

Guselkumab Approved for PsA

Michele B. Kaufman, PharmD, BCGP | August 6, 2020

Based on data from two clinical trials, the FDA has approved guselkumab to treat adult patients with active psoriatic arthritis…

Risankizumab & Apremilast Come to Market in Canada

Michele B. Kaufman, PharmD, BCGP | March 9, 2020

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…

Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins | March 9, 2020

Tildrakizumab Promising for Psoriasis in Patients with PsA

Michele B. Kaufman, PharmD, BCGP | December 2, 2019

New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…

Secukinumab: The Real World Experience of PsA Patients

Michele B. Kaufman, PharmD, BCGP | August 2, 2019

Secukinumab therapy proved safe and effective for psoriatic arthritis patients with multiple co-morbidities and long treatment histories, according to recent research…

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

Michele B. Kaufman, PharmD, BCGP | February 4, 2019

Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…

Tofacitinib Shows Early Potential for Treating Dermatomyositis

Carina Stanton | January 16, 2019

A proof-of-concept study including 10 patients treated for dermatomyositis with tofacitinib, an FDA-approved drug for RA and psoriatic arthritis, shows strong clinical efficacy…

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

Michele B. Kaufman, PharmD, BCGP | January 14, 2019

In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab…